QUILLIVANT ER CHEWABLE TABLETS 40 MG
METHYLPHENIDATE HYDROCHLORIDE : 40 MG · DIN 02541629 · KYE PHARMACEUTICALS INC.
Health Canada status: MARKETED
What is QUILLIVANT ER CHEWABLE TABLETS?
QUILLIVANT ER CHEWABLE TABLETS 40 MG contains METHYLPHENIDATE HYDROCHLORIDE : 40 MG. It is listed in the Health Canada Drug Product Database under DIN 02541629, held by KYE PHARMACEUTICALS INC., supplied as TABLET (CHEWABLE, EXTENDED-RELEASE) for ORAL administration. Health Canada currently lists it as marketed, status dated 24-Jun-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is QUILLIVANT ER CHEWABLE TABLETS used for?
Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children (6-12 years of age).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02541629 |
|---|---|
| Brand name | QUILLIVANT ER CHEWABLE TABLETS |
| Generic / active ingredient | METHYLPHENIDATE HYDROCHLORIDE : 40 MG |
| Manufacturer | KYE PHARMACEUTICALS INC. |
| Strength | 40 MG |
| Dosage form | TABLET (CHEWABLE, EXTENDED-RELEASE) |
| Route of administration | ORAL |
| Schedule | CONTROLLED DRUGS (CDSA III) |
| ATC code | N06BA04 METHYLPHENIDATE |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Jun-2024 |
How is it administered?
Once daily in the morning with or without food. Starting dose 20 mg. Titrate weekly by 10-20 mg. Max dose 60 mg/day. Shake suspension vigorously for 10 seconds. Not interchangeable.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C. Reconstituted suspension is stable for up to 4 months.
How is it supplied?
Suspension: Bottles of 300mg, 600mg, 750mg, 900mg with oral dispenser and adapter. Tablets: Bottles of 100.
Contraindications
Hypersensitivity to methylphenidate or sympathomimetic amines; thyrotoxicosis; advanced arteriosclerosis; symptomatic cardiovascular disease; moderate to severe hypertension; glaucoma; drug abuse.
Warnings and precautions
Potential for abuse/dependence. Sudden death reported in patients with structural cardiac abnormalities. May increase blood pressure/heart rate. Peripheral vasculopathy (Raynaud’s).
What can be used instead?
Other Canadian products sharing ATC code N06BA04 METHYLPHENIDATE. 55 of 103 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACT METHYLPHENIDATE ER | 18 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441934 |
| ACT METHYLPHENIDATE ER | 27 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441942 |
| ACT METHYLPHENIDATE ER | 36 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441950 |
| ACT METHYLPHENIDATE ER | 54 MG | TABLET (EXTENDED-RELEASE) | TEVA CANADA LIMITED | MARKETED | DIN 02441969 |
| APO-METHYLPHENIDATE | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02249324 |
| APO-METHYLPHENIDATE | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02249332 |
| APO-METHYLPHENIDATE | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02273950 |
| APO-METHYLPHENIDATE ER | 18 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452731 |
| APO-METHYLPHENIDATE ER | 27 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452758 |
| APO-METHYLPHENIDATE ER | 36 MG | TABLET (EXTENDED-RELEASE) | APOTEX INC | MARKETED | DIN 02452766 |
Who else supplies METHYLPHENIDATE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. METHYLPHENIDATE appears in 923 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.